Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, but Still Complaining of Excessive Daytime Sleepiness
Phase of Trial: Phase III
Latest Information Update: 02 Dec 2016
At a glance
- Drugs Pitolisant (Primary)
- Indications Hypersomnia
- Focus Therapeutic Use
- Acronyms HAROSA III
- Sponsors Bioprojet
- 02 Dec 2016 Last checked against the ClinicalTrials.gov record.
- 29 Nov 2016 Status changed from recruiting to completed.
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.